Penn Medicine Provider
Pulmonary Medicine
Nuala J. Meyer, MD, MS
Accepting new patients
Sees patients age 18 and up
Penn Heart and Vascular Center

About me

  • Director, Center for Translational Lung Biology
  • Vice Chief for Research, Pulmonary, Allergy, and Critical Care Medicine Division
  • Professor of Medicine (Pulmonary, Allergy and Critical Care) at the Hospital of the University of Pennsylvania

I am board certified in pulmonary and critical care medicine and practice medical critical care. My clinical expertise is in acute respiratory distress syndrome (ARDS) and acute respiratory failure, sepsis and septic shock, and acute organ failure. I am a translational researcher who directs a large molecular cohort study of sepsis to better understand individual ARDS risk, and who seeks to advance precision medicine options for critical illness. I also participate in clinical trials for ARDS and sepsis therapies. 

Education and training

  • Medical School: University of Chicago
  • Residency: University of Chicago Medical Center
  • Fellowship: University of Chicago Medical Center

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
  • Penn Medicine Rittenhouse Long-Term Acute Care Hospital
Dr. Meyer is a Penn Medicine physician.

Qualifications and experience

My research

Mathew D, Giles JR, Baxter AE, Oldridge DA, Greenplate AR, Wu JE, Alanio C, Kuri-Cervantes L, Pampena MB, D'Andrea K, Manne S, Chen Z, Huang YJ, Reilly JP, Weisman AR, Ittner CAG, Kuthuru O, Dougherty J, Nzingha K, Han N, Kim J, Pattekar A, Goodwin EC, Anderson EM, Weirick ME, Gouma S, Arevalo CP, Bolton MJ, Chen F, Lacey SF, Ramage H, Cherry S, Hensley SE, Apostolidis SA, Huang AC, Vella LA, U Penn COVID Processing Unit, Betts MR, Meyer NJ, Wherry EJ Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications , Science, 369(6508): 2020,eabc8511


Kuri-Cervantes L, Pampena MB, Meng W, Rosenfeld AM, Ittner CAG, Weisman, AR, Agyekum RS, Mathew D, Baxter AE, Vella LA, Kuthuru O, Apostolidis SA, Bershaw L, Dougherty J, Greenplate AR, Pattekar A, Kim J, Han N, Gouma S, Weirick ME, Arevalo CP, Bolton MJ, Goodwin EC, Anderson EM, Hensley SE, Jones TK, Mangalmurti NS, Luning Prak ET, Wherry EJ, Meyer NJ, Betts MR Comprehensive mapping of immune perturbations associated with severe COVID-19 , Sci Immunol, 5(49): 2020,eabd7114


Guillen-Guio Beatriz, Lorenzo-Salazar Jose M, Ma Shwu-Fan, Hou Pei-Chi, Hernandez-Beeftink Tamara, Corrales Almudena, García-Laorden M Isabel, Jou Jonathan, Espinosa Elena, Muriel Arturo, Domínguez David, Lorente Leonardo, Martín María M, Rodríguez-Gallego Carlos, Solé-Violán Jordi, Ambrós Alfonso, Carriedo Demetrio, Blanco Jesús, Añón José M, Reilly John P, Jones Tiffanie K, Ittner Caroline Ag, Feng Rui, Schöneweck Franziska, Kiehntopf Michael, Noth Imre, Scholz Markus, Brunkhorst Frank M, Scherag André, Meyer Nuala J, Villar Jesús, Flores Carlos Sepsis-associated acute respiratory distress syndrome in individuals of European ancestry: a genome-wide association study. , The Lancet. Respiratory medicine, 8(3): 2020,258-266


Reilly JP, Wang F, Jones TK, Palakshappa JA, Anderson BJ, Shashaty MGS, Dunn TG, Johansson ED, Riley TR, Lim B, Abbott J, Ittner CAG, Cantu E, Lin X, Mikacenic C, Wurfel MM, Christiani DC, Calfee CS, Matthay MA, Christie JD, Feng R, Meyer NJ Plasma angiopoietin-2 as a potential causal marker in sepsis-associated ARDS development: evidence from Mendelian randomization and mediation analysis. , Intensive Care Med, 44(11): 2018,1849-1858


Meyer Nuala J, Reilly John P, Anderson Brian J, Palakshappa Jessica A, Jones Tiffanie K, Dunn Thomas G, Shashaty Michael G S, Feng Rui, Christie Jason D, Opal Steven M Mortality Benefit of Recombinant Human Interleukin-1 Receptor Antagonist for Sepsis Varies by Initial Interleukin-1 Receptor Antagonist Plasma Concentration. , Critical care medicine, 46(1): 2018,21-28


Reilly JP, Meyer NJ. Shashaty MGS, Anderson BJ, Ittner CAG, Dunn TG, Lim B, Forker CM, Bonk MP, Kotloff ED, Feng R, Cantu E, Mangalmurti NS, Calfee CS, Matthay MA, Mikacenic C, Walley KR, Russell JA, Christiani DC, Wurfel MM, Lanken PN, Reilly MP, Christie JD The ABO Histo-Blood Group, endothelial activation, and acute respiratory distress syndrome risk in critical illness , J Clin Invest, 131(1): 2021,e139700


Jones TK, Feng R, Kerchberger VE, Reilly JP, Anderson BJ, Shashaty MGS, Wang F, Dunn TG, Riley TR, Abbott J, Ittner CAG, Christiani DC, Mikacenic C, Wurfel MM, Ware LB, Calfee CS, Matthay MA, Christie JD, Meyer NJ Plasma sRAGE Acts as Genetically Regulated Causal Intermediate in Sepsis-Associated ARDS. , Am J Respir Crit Care Med, 201(1): 2020,47-56


Meyer NJ, Reilly JP, Feng R, Christie JD, Hazen SL, Albert CJ, Franke JD, Hartman CL, McHowat J, Ford DA Myeloperoxidase-derived 2-chlorofatty acids contribute to human sepsis mortality via acute respiratory distress syndrome. , JCI Insight, 2(23): 2017,e96432


Meyer Nuala J, Calfee Carolyn S Novel translational approaches to the search for precision therapies for acute respiratory distress syndrome. , The Lancet. Respiratory medicine, 5(6): 2017,512-523


Palakshappa Jessica A, Meyer Nuala J Which Patients with ARDS Benefit from Lung Biopsy? , Chest, 148(4): 2015,1073-1082


View all publications